Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.

Toshimi TakanoMitsuya ItoTakayuki Kadoya Tomofumi Osako Tomoyuki Aruga Norikazu MasudaToshiko MiyakiNaoki NiikuraDaisuke ShimizuYuichi YokoyamaManabu WatanabeMasato TomomitsuKenjiro Aogi

Published in: Cancer medicine (2023)

MD-110 was effective against chemotherapy-induced neutropenia. No additional safety concern, compared with the originator, was observed in patients with breast cancer receiving TC chemotherapy.(JapicCTI-205230).

Keyphrases

chemotherapy induced
phase iii
open label
clinical trial
molecular dynamics
double blind
placebo controlled
squamous cell carcinoma
randomized controlled trial
radiation therapy
locally advanced
study protocol